Full-Time

Cloud Security Engineer

Confirmed live in the last 24 hours

Tempus

Tempus

1,001-5,000 employees

Healthcare technology using AI for patient outcomes

Compensation Overview

$120k - $160k/yr

+ Incentive Compensation + Restricted Stock Units

Mid

Company Historically Provides H1B Sponsorship

Chicago, IL, USA

The expected salary range is applicable if the role is performed from Illinois.

Category
Cybersecurity
IT & Security
Required Skills
Microsoft Azure
JIRA
Terraform
Google Cloud Platform
Requirements
  • 3+ Years of overall IT Experience with a major emphasis on Information Security
  • 3+ Years of experience building and integrating systems within cloud providers
  • Strong written and verbal communication skills
  • Strong knowledge of Azure & GCP
  • Proficiency in using APIs with automation to complete tasks
  • Strong problem-solving and decision-making skills and attention to detail
  • Understanding of containerization technologies
  • Experience with log analysis software and techniques
  • Experience working with Jira
  • Knowledge of cyber security frameworks (ISO 27001, NIST 800-53, CIS Controls)
Responsibilities
  • Triage alerts generated by Cloud Security Posture Management Tools
  • Threat Modeling of cloud services
  • Create scripts to achieve a high level of automation
  • Deploy infrastructure as code in cloud environments (Terraform)
  • Conduct POCs, evaluate security tools and foster valuable vendor relationships
  • Configure and create custom monitoring & alerting functions in the cloud
  • Collaborate with Leadership in developing policies and standards for Containerization, Infrastructure as Code, Cloud configurations, Cloud Network Security, and Compute workloads
  • Respond to Cloud Security Incidents and conduct investigations
Desired Qualifications
  • Strong knowledge of AWS
  • AWS/Azure/GCP certifications

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Deep 6 AI expands Tempus' data network and precision medicine capabilities.
  • Partnership with Stemline Therapeutics strengthens Tempus' position in personalized cancer treatment.
  • Collaboration with Artera expands Tempus' reach in oncology diagnostics.

What critics are saying

  • Integration challenges with Deep 6 AI may lead to operational inefficiencies.
  • $560 million debt increases financial leverage, posing a risk if growth falters.
  • Regulatory hurdles may arise in expanding DNA profiling beyond cancer with Illumina.

What makes Tempus unique

  • Tempus uses AI to analyze clinical and molecular data for precision medicine.
  • Their platform aids in personalized cancer treatment through advanced data insights.
  • Tempus collaborates with leading biotech firms to enhance drug development processes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
SDBN
Apr 15th, 2025
Illumina teams up with Tempus to expand DNA profiling beyond cancer

Illumina teams up with Tempus to expand DNA profiling beyond cancer.

Life Care News
Mar 30th, 2025
Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

Tempus exhibits 4 abstracts at the 2025 American College of Cardiology Annual Meeting.

Tempus
Mar 12th, 2025
Tempus Announces Acquisition of Deep 6 AI | Tempus AI

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network CHICAGO --(BUSINESS WIRE)--Mar. 11, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision

TipRanks
Mar 12th, 2025
Tempus AI (TEM) Strengthens Precision Medicine with Deep 6 AI Deal, Cathie Wood Buys the Dip

Tempus AI has acquired Deep 6 AI to expand its reach and enhance offerings in precision medicine.

Business Wire
Feb 25th, 2025
Ares Management Upsizes Tempus Debt Facilities to $560 Million

Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.